August 11, 2006 -- Genzyme filed in Europe to expand the indicated uses of Synvisc, its drug for arthritic joints; Medtronic announced that Horizon Legacy, an instrument set for correcting curvature of the spine, is now available; GlaxoSmithKline will pay $70 million to settle civil lawsuits over its drug pricing; Athersys filed for UK permission to begin human testing of an obesity drug; and Amarillo Biosciences will begin a Phase II trial of low-dose oral interferon in idiopathic pulmonary fibrosis patients. The Centient Biotech 200™ fell 16 points to 3584.30, a loss of .45%. More details...
